IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
- 4 February 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Archives of Pharmacal Research
- Vol. 38 (5), 575-584
- https://doi.org/10.1007/s12272-015-0569-8
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by polyarthritis. Numerous agents with varying mechanisms are used in the treatment of RA, including non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and some biological agents. Studies to uncover the cause of RA have recently ended up scrutinizing the importance of pro-inflammatory cytokine such as tumor necrosis factor α (TNF-α) and interleukin (IL)-6 in the pathogenesis of RA. TNF-α inhibitors are increasingly used to treat RA patients who are non-responsive to conventional anti-arthritis drugs. Despite its effectiveness in a large patient population, up to two thirds of RA patients are found to be partially responsive to anti-TNF therapy. Therefore, agents targeting IL-6 such as tocilizumab (TCZ) attracted significant attention as a promising agent in RA treatment. In this article, we review the mechanism of anti-IL-6 in the treatment of RA, provide the key efficacy and safety data from clinical trials of approved anti-IL-6, TCZ, as well as six candidate IL-6 blockers including sarilumab, ALX-0061, sirukumab, MEDI5117, clazakizumab, and olokizumab, and their future perspectives in the treatment of RA.Keywords
This publication has 36 references indexed in Scilit:
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyAnnals Of The Rheumatic Diseases, 2014
- Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a reviewPatient Preference and Adherence, 2013
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialThe Lancet, 2013
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Annals Of The Rheumatic Diseases, 2012
- Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended PharmacokineticsJournal of Molecular Biology, 2011
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI studyModern Rheumatology, 2011
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis & Rheumatism, 2009
- Cost-Effectiveness of Biologics as First-Line Treatment of Rheumatoid Arthritis: Case Closed?Annals of Internal Medicine, 2009
- Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptorRheumatology, 2009
- Treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy, 2006